Two major diabetes drug companies, Pfizer and Bristol-Myers Squibb, are set to partner up to generate new medicines for diabetes and obesity. The established pharmaceutical companies now face considerable competition from other generic medicine.
The new collaboration will be centred around a set of compounds classed as DGAT-1 inhibitors. This family blocks the creation and storage of fat, and could play a principal role in the evolution of new medical treatments. Both companies are based in New York .
The business deal is expected to be a partnership, with Bristol paying Pfizer to research, and Pfizer fronting costs and getting greater profit share . City analysts take the partnership as a reaction against falling sales of major cash -generating drugs.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…